FDA backs Roche's Gazyva in first-line follicular lymphoma
ZURICH (Reuters) - The U.S. Food and Drug Administration on Thursday expanded approvals for Roche's Gazyva to include previously untreated follicular lymphoma, bolstering the Swiss drugmaker's efforts to strengthen its portfolio of blood cancer medicines.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health | Lymphoma | Switzerland Health